Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

361. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. (PubMed)

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Chronic obstructive pulmonary disease (COPD) is a growing cause of morbidity and mortality worldwide, and accurate estimates of the prevalence of this disease are needed to anticipate the future burden of COPD, target key risk factors, and plan for providing COPD-related health services. We aimed to measure the prevalence of COPD and its risk factors and investigate variation across (...) countries by age, sex, and smoking status.Participants from 12 sites (n=9425) completed postbronchodilator spirometry testing plus questionnaires about respiratory symptoms, health status, and exposure to COPD risk factors. COPD prevalence estimates based on the Global Initiative for Chronic Obstructive Lung Disease staging criteria were adjusted for the target population. Logistic regression was used to estimate adjusted odds ratios (ORs) for COPD associated with 10-year age increments and 10-pack-year

2007 Lancet

362. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. (PubMed)

Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality in China, where the population is also exposed to high levels of passive smoking, yet little information exists on the effects of such exposure on COPD. We examined the relation between passive smoking and COPD and respiratory symptoms in an adult Chinese population.We used baseline data from the Guangzhou Biobank (...) Cohort Study. Of 20 430 men and women over the age of 50 recruited in 2003-06, 15,379 never smokers (6497 with valid spirometry) were included in this cross-sectional analysis. We measured passive smoking exposure at home and work by two self-reported measures (density and duration of exposure). Diagnosis of COPD was based on spirometry and defined according to the GOLD guidelines.There was an association between risk of COPD and self-reported exposure to passive smoking at home and work (adjusted

2007 Lancet

363. What have we learned from large drug treatment trials in COPD? (PubMed)

What have we learned from large drug treatment trials in COPD? Although the development of effective treatments for patients with chronic obstructive pulmonary disease (COPD) has not been seen as a high priority, the past decade has seen a substantial increase in the number of clinical studies examining different treatments for this disease. Large studies are needed to adequately assess the effectiveness of treatment because of the chronic nature of the disease and the intermittent occurrence (...) , but results of these studies can be affected by differences in inclusion criteria and patient dropout during the study. Bronchodilator reversibility testing does not reliably define subgroups that will respond to a particular treatment. Carefully done and adequately powered clinical trials continue to inform, not only our views about treatment, but also our understanding of COPD and how it is best assessed and managed. Ensuring that these expensive studies are done objectively to the highest standard

2007 Lancet

364. Global burden of COPD: risk factors, prevalence, and future trends. (PubMed)

Global burden of COPD: risk factors, prevalence, and future trends. Chronic obstructive pulmonary disease (COPD) continues to be an important cause of morbidity, mortality, and health-care costs worldwide. It is a global health issue, with cigarette smoking being an important risk factor universally; other factors, such as exposure to indoor and outdoor air pollution, occupational hazards, and infections, are also important. As the global population ages, the burden of COPD will increase (...) in years to come. Prevalence estimates of the disorder show considerable variability across populations, suggesting that risk factors can affect populations differently. Other advances in our understanding of COPD are increased recognition of the importance of comorbid disease, identification of different COPD phenotypes, and understanding how factors other than lung function affect outcome in our patients. The challenge we will all face in the next few years will be implementation of cost-effective

2007 Lancet

365. COPD exacerbations: defining their cause and prevention. (PubMed)

COPD exacerbations: defining their cause and prevention. Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of worsening of symptoms, leading to substantial morbidity and mortality. COPD exacerbations are associated with increased airway and systemic inflammation and physiological changes, especially the development of hyperinflation. They are triggered mainly by respiratory viruses and bacteria, which infect the lower airway and increase airway inflammation. Some (...) patients are particularly susceptible to exacerbations, and show worse health status and faster disease progression than those who have infrequent exacerbations. Several pharmacological interventions are effective for the reduction of exacerbation frequency and severity in COPD such as inhaled steroids, long-acting bronchodilators, and their combinations. Non-pharmacological therapies such as pulmonary rehabilitation, self-management, and home ventilatory support are becoming increasingly important

2007 Lancet

366. Review: cardioselective ß blockers do not produce adverse respiratory effects in COPD

Review: cardioselective ß blockers do not produce adverse respiratory effects in COPD Review: cardioselective β blockers do not produce adverse respiratory effects in COPD | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: cardioselective β blockers do not produce adverse respiratory effects in COPD Article Text Therapeutics Review: cardioselective β blockers do not produce adverse respiratory effects in COPD Statistics from

2007 Evidence-Based Medicine (Requires free registration)

367. A 68-year-old man with COPD contemplating colon cancer surgery. (PubMed)

A 68-year-old man with COPD contemplating colon cancer surgery. Mr A is a 68-year-old man with a history of melena who was found to have a mass in his colon that was suspicious for possible malignancy. His 75-pack-year smoking history has resulted in a chronic daily cough and the diagnosis of chronic obstructive pulmonary disease. On physical examination, he has wheezes, decreased breath sounds, and a prolonged expiratory phase; his forced expiratory volume in the first second (FEV1) is 1.34 L

2007 JAMA

368. Systematic review of noninvasive positive pressure ventilation in severe stable COPD

Systematic review of noninvasive positive pressure ventilation in severe stable COPD Systematic review of noninvasive positive pressure ventilation in severe stable COPD Systematic review of noninvasive positive pressure ventilation in severe stable COPD Kolodziej M A, Jensen L, Rowe B, Sin D CRD summary The authors concluded that bi-level non-invasive positive pressure ventilation may be a useful adjunct for a subset of patients with severe stable chronic obstructive pulmonary disease (...) . Findings appeared to support the conclusions, but the assessment of multiple outcomes from generally small short-term studies meant that the evidence was limited and caution is advised. Authors' objectives To evaluate the effectiveness of bi-level non-invasive positive pressure ventilation (NIPPV) in patients with chronic respiratory failure (CRF) due to severe stable chronic obstructive pulmonary disease (COPD). Searching MEDLINE/Pre-MEDLINE/PubMed, EMBASE, CINAHL, Conference Papers Index, Online

Full Text available with Trip Pro

2007 DARE.

369. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients

Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients Dal Negro R, Eandi M, Pradelli L, Iannazzo S Record Status (...) pulmonary disease (COPD), in agreement with the Global Initiative for Chronic Lung Disease (GOLD) recommendations. These included: combined salmeterol/fluticasone (SF), 50/500 μg twice daily (b.i.d.) in GOLD Stages III and IV patients in addition to the standard therapy already in use; combined formoterol/budesonide (FB), 160/4.5 μg b.i.d. in GOLD Stages III and IV patients in addition to the standard therapy already in use. The comparators were: fluticasone, 500 μg b.i.d. in GOLD Stages III and IV

2007 NHS Economic Evaluation Database.

370. Intermediate care - Hospital at Home in COPD

Intermediate care - Hospital at Home in COPD BTS GUIDELINES Intermediate care—Hospital-at-Home in chronic obstructive pulmonary disease: British Thoracic Society guideline British Thoracic Society Guideline Development Group* Thorax 2007;62:200–210. doi: 10.1136/thx.2006.064931 Correspondence to: Dr R Stevenson, Department of Respiratory Medicine, Glasgow Royal Infirmary, Glasgow G31 2ER, UK; robin.stevenson@ northglasgow.scot.nhs.uk Received 5 May 2006 Accepted 23 August 2006 I ntermediate (...) review concluded that HaH was a safe and effective treatment approach for selected patients with exacerbations of chronic obstructive pulmonary disease (COPD), and suggested that one in four patients presenting to hospital as an emergency would be suitable for home treatment with nursing support, 1 although some felt that this was an underestimate of eligibility for HaH (Stevenson, 2005). In 2004 the National Institute for Clinical Excellence (NICE) COPD guidelines 2 included appraisal of HaH

2007 British Thoracic Society

371. Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life

Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life Article Text Therapeutics Review: tiotropium reduces exacerbations and hospital

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

372. Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness

Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness Article Text Qualitative Patients with acute exacerbations of COPD saw anxiety

Full Text available with Trip Pro

2006 Evidence-Based Nursing

373. Administration of steroids in acute exacebations of COPD

Administration of steroids in acute exacebations of COPD BestBets: Administration of steroids in acute exacerbations of COPD Administration of steroids in acute exacerbations of COPD Report By: Shweta Gidwani - Clinical Effectiveness Fellow in Emergency Medicine Search checked by Craig Ferguson - Clinical Research Fellow Institution: Manchester Royal Infirmary Date Submitted: 8th June 2005 Date Completed: 8th February 2006 Last Modified: 8th June 2005 Status: Green (complete) Three Part (...) Question In [patients with an acute exacerbation of COPD] are [steroids prior to discharge better than no steroids] at [improving outcome and hastening recovery]? Clinical Scenario A 55yr old man, known to have COPD comes to casulty more short of breath than usual and with a history of recently coughing purulent sputum. You treat him in the ED with continuous nebulised bronchodilater therapy, oral steroids as well as antibiotics. He starts to improve and on reasessing him clinically, after reviewing

2006 BestBETS

374. Chronic obstructive pulmonary disease (COPD)

Chronic obstructive pulmonary disease (COPD) INTRODUCTION Chronic obstructive pulmonary disease (COPD) is a general term that covers a variety of previously used labels which are now recognised as different aspects of the same underlying problem. The term COPD encompasses: ? chronic bronchitis ? emphysema ? chronic obstructive airways disease (COAD) ? chronic obstructive lung disease (COLD) ? chronic air?ow limitation disease (CALD) ? some cases of chronic asthma. COPD is a chronic progressive (...) disorder characterised by airway obstruction that does not change markedly over several months. Whilst the impairment is considered permanent it may be partially reversible (at least transiently) by bronchodilator and/or other therapies. Patients with COPD usually present to the ambulance service with an acute exacerbation of the underlying illness. COPD is a concomitant/secondary illness in many incidents with other chief complaints. Some patients with severe COPD may carry information (e.g. a card

2006 Joint Royal Colleges Ambulance Liaison Committee

375. A meta-analysis on the efficacy of oral theophylline in patients with stable COPD

A meta-analysis on the efficacy of oral theophylline in patients with stable COPD A meta-analysis on the efficacy of oral theophylline in patients with stable COPD A meta-analysis on the efficacy of oral theophylline in patients with stable COPD Molfino N A, Zhang P CRD summary The authors concluded that oral theophylline improved both trough and peak forced expiratory volume and forced vital capacity in patients with stable chronic obstructive pulmonary disease. Given the methodological (...) limitations of the review, and the unknown quality of the included trials, the authors' conclusions may not be reliable. Authors' objectives To evaluate the efficacy of oral theophylline in patients with stable chronic obstructive pulmonary disease (COPD). Searching PubMed was searched for English language publications up to June 2005. Search terms were reported. References from relevant systematic reviews were also checked for additional studies. Study selection Randomised controlled trials (RCTs

2006 DARE.

376. Pulmonary rehabilitation for COPD and other lung diseases

Pulmonary rehabilitation for COPD and other lung diseases Pulmonary rehabilitation for COPD and other lung diseases Pulmonary rehabilitation for COPD and other lung diseases Trikalinos TA, Raman G, Kupelnick B, Chew PW, Lau J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Trikalinos TA, Raman G, Kupelnick B, Chew PW, Lau J. Pulmonary (...) rehabilitation for COPD and other lung diseases. Rockville: Agency for Healthcare Research and Quality (AHRQ). Technology Assessment. 2006 Authors' objectives This technology assessment summarizes the available evidence on the efficacy and safety of pulmonary rehabilitation (PR) interventions, and describes the influence of patient-level or study-level characteristics. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Pulmonary Disease, Chronic Obstructive /rehabilitation Language

2006 Health Technology Assessment (HTA) Database.

377. Herbal medicines for the treatment of COPD: a systematic review

Herbal medicines for the treatment of COPD: a systematic review Herbal medicines for the treatment of COPD: a systematic review Herbal medicines for the treatment of COPD: a systematic review Guo R, Pittler M H, Ernst E CRD summary This review found no conclusive evidence of the effectiveness of herbal medicines for the treatment of chronic obstructive pulmonary disease. The evidence from studies was scarce and often methodologically weak. The authors' cautious conclusions correctly reflect (...) the poor quality trials and paucity of data on this topic. Authors' objectives To evaluate the effectiveness of herbal medicines for the treatment of chronic obstructive pulmonary disease (COPD). Searching AMED, MEDLINE, EMBASE, CINAHL and the Cochrane Library were searched from inception to August 2005. No language restrictions were applied. Search terms were reported. Handsearching of some journals was conducted. Three manufacturers were contacted for further relevant data. Also, reference lists

2006 DARE.

378. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. (PubMed)

Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. PURPOSE: We wanted to review systematically the efficacy, effectiveness, and safety of inhaled corticosteroids with respect to health outcomes in patients with chronic obstructive pulmonary disease (COPD). METHODS: We searched MEDLINE, EMBASE, The Cochrane Library, and the International Pharmaceutical Abstracts to identify relevant articles. We limited evidence (...) corticosteroid treatment in patients with asthma or COPD. Overall, COPD patients treated with inhaled corticosteroids experienced significantly fewer exacerbations than patients taking placebo (relative risk [RR] = 0.67; 95% CI, 0.59-0.77). No significant difference could be detected for overall mortality (RR = 0.81; 95% CI, 0.60-1.08). Evidence on quality of life, functional capacity, and respiratory tract symptoms is mixed. Adverse events were generally tolerable; pooled discontinuation rates did

Full Text available with Trip Pro

2006 EvidenceUpdates

379. Review: inhaled corticosteroids slow the progression of airflow limitation in COPD

Review: inhaled corticosteroids slow the progression of airflow limitation in COPD Review: inhaled corticosteroids slow the progression of airflow limitation in COPD | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: inhaled corticosteroids slow the progression of airflow limitation in COPD Article Text Therapeutics Review: inhaled corticosteroids slow the progression of airflow limitation in COPD Free Michael Greenstone , MD, FRCP

Full Text available with Trip Pro

2005 Evidence-Based Medicine (Requires free registration)

380. Nursing care of dyspnea: the 6th vital sign in individuals with chronic obstructive pulmonary disease (COPD).

Nursing care of dyspnea: the 6th vital sign in individuals with chronic obstructive pulmonary disease (COPD). Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines

2005 Registered Nurses' Association of Ontario